Tekla Accounts Payable from 2010 to 2026
| HQL Stock | | | USD 16.37 -0.25 -1.50% |
Over extended periods, Accounts Payable is broadly receding with intermittent volatility. Accounts Payable is the amount Tekla Life Sciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Tekla Life's short-term liabilities.
View All Fundamentals Accounts Payable | First Reported 1996-09-30 | Previous Quarter 6.5 M | Current Value 720.9 K | Quarterly Volatility 3 M |
Macro event markers
Dot-com Bubble | Housing Crash | Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
provides competitor comparison context for Tekla Life. This provides competitive positioning context.
Historical Accounts Payable data for Tekla Life serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Tekla Life Sciences represents a compelling investment opportunity.
Latest Tekla Life's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Tekla Life Sciences over the last few years. An accounting item on the balance sheet that represents Tekla Life obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tekla Life Sciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Tekla Life's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend | | |
Tekla Accounts Payable Regression Statistics
| Arithmetic Mean | 1,244,161 |
| Geometric Mean | 295,113 |
| Coefficient Of Variation | 125.64 |
| Mean Deviation | 1,227,219 |
| Median | 720,901 |
| Standard Deviation | 1,563,220 |
| Sample Variance | 2.4T |
| Range | 5.1M |
| R-Value | -0.0023 |
| Mean Square Error | 2.6T |
| R-Squared | 0.00000532 |
| Significance | 0.99 |
| Slope | -713.93 |
| Total Sum of Squares | 39.1T |
Tekla Accounts Payable History
| 2026 | 787.6 K | |
| 2025 | 829 K | |
| 2024 | 720.9 K | |
| 2022 | 1791.0 | |
| 2021 | 5.1 M | |
| 2019 | 150.3 K | |
| 2018 | 2.8 M | |
Stock Overview, Methodology & Data Sources
The stock is still going through the normal trading activities.Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange. The profile for Tekla Life integrates fundamentals, price behavior, and sector exposure. Historical patterns suggest somewhat reduced sensitivity to broader economic swings. Tekla Life has a market cap of 484.53 M, P/E of 2.84, ROE of 17.59%.
Methodology
Unless otherwise specified, financial data for Tekla Life Sciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Tekla (USA Stocks:HQL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Tekla Life Sciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try Portfolio ProphetMore Resources for Tekla Stock Analysis
Reviewing Tekla Life Sciences commonly begins with
financial statements and performance trends. Ratio context helps frame profitability, efficiency, and growth trends for Tekla Life Sciences Stock.
Key reports that frame Tekla Life Sciences Stock are listed below: Tekla Life Correlation provides competitor comparison context for Tekla Life. This provides competitive positioning context.
Analysis related to Tekla Life should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth -0.70 |
Investors evaluate Tekla Life Sciences using market value and book value, each describing different facets of the business. Tekla Life's market capitalization is 484.53 M. A P/B ratio of 0.94 suggests Tekla Life trades near or below book value. Enterprise value stands at 484.46 M. Intrinsic value reflects what Tekla Life's
fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
The concept of value for Tekla Life differs from its quoted price, since each reflects a different lens. For Tekla Life, key inputs include a P/E ratio of 2.84, a P/B ratio of 0.94, a profit margin of 44.16%, and ROE of 17.59%. The quoted price is simply the exchange level where supply meets demand.